Brazil Contradicts Bharat Biotech Claim On Emergency Approval For Covaxin | Read

PUBLISHED ON: July 5, 2021 | Duration: 3 min, 20 sec

  
loading..
Controversy over a $324 million deal between Brazil and Bharat Biotech - for the import of 20 million doses of the 'made-in-India' COVID-19 vaccine Covaxin - continues to grow, with reports from the South American country saying its national health regulatory authority - ANVISA - had never actually granted the Hyderabad-based manufacturer an EUA (emergency use application).
ALSO WATCH
Mumbai Covid Cases Down 83% From Jan 7 Peak, Positivity Slides To 7%

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com